Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Cut by First Hawaiian Bank

First Hawaiian Bank lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 96.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 4,000 shares of the biopharmaceutical company’s stock after selling 106,000 shares during the quarter. First Hawaiian Bank’s holdings in Alnylam Pharmaceuticals were worth $598,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Norges Bank bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $390,438,000. Capital International Investors increased its stake in shares of Alnylam Pharmaceuticals by 15.8% during the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after acquiring an additional 488,814 shares during the period. Wellington Management Group LLP increased its stake in shares of Alnylam Pharmaceuticals by 6.0% during the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after acquiring an additional 364,021 shares during the period. Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares during the period. Finally, abrdn plc raised its stake in shares of Alnylam Pharmaceuticals by 910.7% in the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock worth $44,544,000 after buying an additional 209,691 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 5.3 %

Shares of ALNY opened at $165.70 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $218.88. The stock has a 50 day simple moving average of $150.49 and a 200-day simple moving average of $162.41. The stock has a market cap of $20.96 billion, a PE ratio of -61.83 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.40) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ALNY shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $283.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. Chardan Capital reiterated a “buy” rating and issued a $225.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. HC Wainwright upped their price target on Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $220.12.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at $1,253,589.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.